GSK3915393: An In-Depth Analysis of a Novel Transglutaminase 2 Inhibitor for Idiopathic Pulmonary Fibrosis

Executive Summary

This report provides an exhaustive analysis of GSK3915393, an investigational small molecule inhibitor of transglutaminase 2 (TG2) developed by GlaxoSmithKline (GSK). The drug represents a novel therapeutic approach for Idiopathic Pulmonary Fibrosis (IPF), a chronic, progressive, and fatal lung disease with a significant unmet medical need. GSK3915393 works by targeting the TG2 enzyme, a key driver of the fibrotic process through its role in extracellular matrix (ECM) cross-linking and myofibroblast activation.

Initially acquired through the 2019 buyout of Sitari Pharmaceuticals, GSK3915393 was first evaluated for the treatment of celiac disease. However, in early 2023, GSK strategically discontinued the celiac disease program, citing a disciplined approach to capital allocation and R&D prioritization rather than any reported failure of the drug's mechanism or safety. The development program was subsequently pivoted to focus entirely on IPF, an indication with a more severe prognosis and a well-defined regulatory pathway.

The clinical development of GSK3915393 has been characterized by a meticulous and strategically de-risked approach. A comprehensive Phase 1 program has been completed, assessing the drug's safety, tolerability, and pharmacokinetics (PK) in healthy volunteers of diverse ethnic backgrounds. Crucially, these early studies also proactively investigated potential drug-drug interactions (DDIs) with CYP3A4 inhibitors and with nintedanib, a current standard-of-care therapy for IPF. This early focus on combination potential and metabolic pathways underscores a sophisticated, long-term development strategy aimed at positioning GSK3915393 as both a potential monotherapy and an add-on treatment.

Currently, GSK3915393 is in a pivotal Phase 2 clinical trial, TRANSFORM (NCT06317285), a randomized, placebo-controlled study designed to evaluate its efficacy and safety in approximately 150 participants with IPF. The primary endpoint is the absolute change from baseline in Forced Vital Capacity (FVC) at 26 weeks, a well-established surrogate for disease progression in IPF. The trial design allows for the inclusion of patients both on and off current standard-of-care antifibrotics, providing maximum flexibility for future market positioning.

The competitive landscape in IPF is dominated by two approved drugs, nintedanib and pirfenidone, which slow but do not halt or reverse disease progression and are associated with significant tolerability issues. The novel mechanism of action of GSK3915393 offers the potential for an improved efficacy and safety profile, which could be a key differentiator. The future success of GSK3915393 hinges on the outcomes of the TRANSFORM study. Positive results would validate TG2 as a therapeutic target in IPF and position GSK3915393 as a significant new entrant in a market with a pressing need for more effective and better-tolerated treatments.

Introduction to GSK3915393 and its Target, Transglutaminase 2 (TG2)

Drug Profile and Origin

GSK3915393 is a novel, investigational small molecule being developed by the global pharmaceutical company GlaxoSmithKline (GSK).[1] It is designed to act as a selective inhibitor of the enzyme transglutaminase 2, also known as tissue transglutaminase or TGM2.[2] As a therapeutic agent, it is classified primarily as an antifibrotic, reflecting its current development focus on fibrotic diseases.[7] The drug has been formulated for both oral (capsule) and intravenous administration in its clinical trial programs.[1]

The asset's journey into GSK's pipeline is a result of a strategic acquisition. In 2019, GSK purchased Sitari Pharmaceuticals, a biotechnology company it had helped establish a decade prior.[9] This acquisition brought GSK3915393, Sitari's lead candidate, in-house, signaling GSK's long-standing interest in the TG2 pathway and its therapeutic potential. Initially, the development program was focused on celiac disease, where the drug was classified as a potential digestion aid.[7] However, following early-phase studies, GSK made a strategic decision to pivot development toward Idiopathic Pulmonary Fibrosis (IPF), where the drug is now in Phase 2 clinical trials.[4]

The Multifunctional Role of Transglutaminase 2 (TG2)

Transglutaminase 2 (TG2) is a unique and complex enzyme with a broad range of biological functions. It is a member of the transglutaminase family, which are calcium-dependent enzymes that catalyze the post-translational modification of proteins.[10] The most well-characterized function of TG2 is its transamidation activity, where it forms highly stable, covalent isopeptide bonds between the γ-carboxamide group of a peptide-bound glutamine residue and the ε-amino group of a lysine residue. This cross-linking activity renders target proteins, particularly those in the extracellular matrix (ECM), more resistant to proteolytic degradation.[11]

TG2 is ubiquitously expressed and found in multiple cellular compartments, including the cytosol, nucleus, mitochondria, and on the cell surface, as well as being secreted into the extracellular space.[10] This widespread distribution reflects its involvement in a diverse array of cellular processes beyond simple protein cross-linking, including cell adhesion, cell migration, signal transduction, apoptosis, and the organization and stabilization of the ECM.[10] While TG2 plays important roles in normal physiological processes such as wound healing and tissue repair, its dysregulation is a key factor in the pathogenesis of a range of diseases, most notably autoimmune conditions like celiac disease and various chronic fibrotic diseases, including IPF.[11] Its central role in these pathological processes makes it a compelling target for therapeutic intervention.

Characteristic	Description	Source(s)
Drug Name	GSK3915393	1
Synonyms	GSK-3915393, GSK 3915393	2
Developer/Originator	GlaxoSmithKline (GSK)	1
Modality	Small Molecule	1
Drug Class	Antifibrotics; Digestion aids (former)	7
Mechanism of Action (MoA)	Transglutaminase 2 (TGM2) inhibitor	2
Route of Administration	Oral, Intravenous	1
Active Indication	Idiopathic Pulmonary Fibrosis (IPF); Pulmonary Fibrosis	3
Discontinued Indication	Celiac Disease	1
Highest Development Phase	Phase 2	2

The Scientific Rationale: Targeting TG2 in Disease

The therapeutic strategy for GSK3915393 is predicated on the central role its target, transglutaminase 2 (TG2), plays in the pathophysiology of distinct diseases. The rationale for its development has evolved, shifting from an initial focus on the autoimmune mechanisms of celiac disease to the progressive fibrotic processes of Idiopathic Pulmonary Fibrosis (IPF).

Rationale in Idiopathic Pulmonary Fibrosis (IPF)

IPF is a devastating chronic lung disease characterized by the relentless and progressive scarring, or fibrosis, of lung tissue. This process leads to the destruction of normal lung architecture, resulting in impaired lung function, severe breathing difficulties, and ultimately, respiratory failure.[8] The prognosis for IPF is grim, with a median survival of only 2 to 3 years after diagnosis.[13]

A substantial body of evidence identifies TG2 as a key driver of the fibrotic cascade in IPF. Both the expression and enzymatic activity of TG2 are significantly upregulated in the lung tissue of patients with IPF and in preclinical models of lung fibrosis.[10] The profibrotic effects of TG2 are multifaceted:

1. Extracellular Matrix (ECM) Stabilization: TG2's primary enzymatic function is to cross-link ECM proteins, such as collagen and fibronectin. This action creates a highly stable, protease-resistant matrix that accumulates in the lung interstitium, contributing directly to the physical scarring and tissue stiffening that define the disease.[12]
2. Myofibroblast Activation and Function: Fibroblasts and their differentiated counterparts, myofibroblasts, are the principal effector cells in fibrosis, responsible for the excessive production of ECM components. TG2 promotes the differentiation of fibroblasts into the more aggressive myofibroblast phenotype and enhances their contractile and migratory functions, further perpetuating the fibrotic cycle.[10]
3. Cell-Matrix Signaling: On the cell surface, TG2 acts as a co-receptor, binding to integrins and enhancing cellular adhesion to the fibronectin-rich matrix. This interaction promotes a pro-fibrotic signaling cascade within the cell, leading to increased ECM production.[13]

The validation of TG2 as a therapeutic target is strongly supported by genetic studies. Preclinical research has shown that TG2 knockout mice are protected from developing severe lung scarring in the bleomycin-induced model of pulmonary fibrosis, a standard experimental paradigm for studying the disease.[10] Based on this extensive evidence, the therapeutic hypothesis for GSK3915393 in IPF is that by inhibiting the enzymatic activity of TG2, the drug will disrupt these core pathological processes. It is expected to reduce the stabilization and accumulation of the fibrotic ECM and attenuate myofibroblast activation, thereby slowing the progressive decline in lung function that is the hallmark of IPF.[16]

Rationale in Celiac Disease (Discontinued)

Prior to its focus on IPF, GSK3915393 was developed for celiac disease, an autoimmune disorder triggered by the ingestion of gluten in genetically susceptible individuals.[19] The disease is characterized by an immune-mediated attack on the lining of the small intestine, leading to villous atrophy, malabsorption, and a range of gastrointestinal and systemic symptoms.[19]

The scientific rationale for targeting TG2 in celiac disease is exceptionally strong, as the enzyme is directly implicated in initiating the pathogenic immune response. In the gut, TG2 performs two critical actions on gluten peptides (specifically gliadin) that render them highly immunogenic:

1. Deamidation: TG2 catalyzes the deamidation of specific glutamine residues within gliadin peptides. This chemical modification introduces a negative charge, dramatically increasing the binding affinity of these peptides for the disease-associated human leukocyte antigen (HLA) molecules, HLA-DQ2 or HLA-DQ8, which are present on the surface of antigen-presenting cells. This enhanced binding leads to the robust activation of gluten-specific CD4+ T-cells, which orchestrate the subsequent inflammatory cascade and tissue damage.[15]
2. Cross-linking and Autoantigen Formation: In addition to deamidation, TG2 can also cross-link gliadin peptides to itself, forming novel TG2-gliadin complexes. These complexes are recognized by the immune system, leading to a break in self-tolerance and the generation of the highly specific anti-TG2 autoantibodies that are a serological hallmark of the disease.[15]

The therapeutic hypothesis was that by blocking the enzymatic activity of TG2 with GSK3915393, the initial modification of gluten could be prevented. This would theoretically stop the pathogenic cascade at its source, averting the activation of the adaptive immune response and protecting the intestinal mucosa from damage.[1]

Strategic Pivot from Celiac Disease to Idiopathic Pulmonary Fibrosis

In a significant strategic shift announced in early 2023, GSK discontinued the development of GSK3915393 for celiac disease and redirected the program to focus on IPF.[9] This decision was not attributed to a failure of the drug's mechanism or any reported safety concerns from the Phase 1 studies. Instead, GSK's leadership framed the move as a deliberate act of R&D portfolio prioritization and disciplined capital allocation.[9]

An analysis of the differing therapeutic landscapes of the two diseases provides a clear rationale for this pivot. While celiac disease is a chronic and burdensome condition, its established, albeit challenging, standard of care is a strict gluten-free diet.[20] The regulatory path for a new adjunctive therapy would require demonstrating significant benefit on top of this dietary management, a potentially high bar to clear. Furthermore, the market is characterized by a number of competing therapeutic approaches under investigation.[23]

In stark contrast, IPF is a relentlessly progressive and fatal disease with a high unmet medical need. The existing standard-of-care treatments, nintedanib and pirfenidone, only slow the rate of functional decline and are hampered by significant tolerability issues.[25] For IPF, slowing the decline in FVC is a well-established and accepted primary endpoint for regulatory approval. This provides a clearer and potentially more streamlined development pathway compared to celiac disease. The decision to pivot suggests a calculated assessment by GSK that the potential for significant patient impact, coupled with a more favorable regulatory and commercial landscape, was substantially greater in IPF. This move highlights a corporate strategy focused on deploying resources toward assets with the highest probability of technical, regulatory, and commercial success in areas of profound unmet medical need.

Preclinical and Clinical Development Program: A Comprehensive Analysis

The development pathway for GSK3915393 has been methodical, progressing from foundational safety and pharmacokinetic assessments to its current focus on efficacy in Idiopathic Pulmonary Fibrosis (IPF). The program is notable for its strategic adaptations and proactive investigation of key clinical questions early in development.

Preclinical Data

Detailed preclinical data for GSK3915393 are not extensively available in the public domain.[2] However, the advancement of the molecule into Phase 1 and subsequently Phase 2 clinical trials presupposes the existence of a comprehensive preclinical data package. This package would have necessarily demonstrated sufficient target engagement, a plausible mechanism of action, and an acceptable safety profile in animal models to warrant investigation in humans. The scientific rationale is strongly buttressed by a wealth of independent preclinical literature validating TG2 as a therapeutic target in models of fibrosis, showing that genetic ablation or inhibition of TG2 mitigates fibrotic processes.[10]

Phase 1 Clinical Program: Establishing the Foundation

GSK initiated a multi-part Phase 1 program to thoroughly characterize the safety, tolerability, and pharmacokinetic (PK) profile of GSK3915393.

First-in-Human and Dose Escalation Study (IRAS ID: 1003407 / EudraCT: 2020-003213-36)

The first-in-human trial for GSK3915393 was initiated in October 2020. It was designed as a randomized, placebo-controlled, double-blind study with a complex, multi-part structure.[19]

• Part A and B: These parts involved single and repeat dose-escalation in healthy adult volunteers (up to 12 and 36 participants, respectively) to establish the initial safety and PK profile of the drug.[19] Dosing was primarily via oral capsules, but Part A also included a single intravenous 'microdose' to obtain absolute bioavailability data.[19]
• Part C (Original Design): This part was initially designed to evaluate the safety, tolerability, PK, and pharmacodynamics (PD) of GSK3915393 in 20 adult patients with celiac disease. A key component was a gluten challenge, where participants would consume gluten to assess if the drug could blunt the body's pathogenic reaction.[19]
• Status: This study has been completed. However, GSK has not yet published a detailed summary of the results from the healthy volunteer or celiac patient cohorts.[19]

Drug-Drug Interaction Study (NCT04604795)

The clinical trial identifier NCT04604795 is associated with the initial Phase 1 study, which underwent a significant protocol amendment. The original Part C, the gluten challenge in celiac patients, was replaced with a drug-drug interaction (DDI) investigation in healthy participants.[1]

• Rationale for Amendment: This change was prompted by new in-vitro data indicating that GSK3915393 is a substrate for the cytochrome P450 3A4 (CYP3A4) enzyme in both the liver and the intestine.[31]
• Study Objective: The amended study aimed to quantify the clinical significance of this metabolic pathway by assessing the effects of co-administration with known CYP3A4 inhibitors. Participants were given GSK3915393 along with grapefruit juice (a moderate intestinal CYP3A4 inhibitor) and itraconazole (a strong systemic CYP3A4 inhibitor).[1]
• Status: This DDI study has been completed.[4] The results, while not publicly detailed, are critical for establishing safe dosing guidelines and identifying prohibited or cautioned concomitant medications for all subsequent clinical trials, particularly in a patient population like IPF where polypharmacy is common.

Ethnic Pharmacokinetics and Nintedanib Interaction Study (NCT06625489)

To support global development and a potential combination therapy strategy in IPF, GSK conducted a further dedicated Phase 1 study that completed in November 2024.[2]

• Part A: This part evaluated the safety, tolerability, and PK of single doses of GSK3915393 in healthy participants of Chinese, Japanese, and European ancestry. This is a crucial step for understanding potential ethnic differences in drug metabolism and exposure, facilitating simultaneous global clinical development.[2]
• Part B: This part assessed the DDI potential between GSK3915393 and nintedanib, one of the two approved standard-of-care antifibrotic agents for IPF. Healthy volunteers received single doses of both drugs to evaluate if GSK3915393 alters the blood levels of nintedanib, and vice-versa.[33]
• Status: This study is completed. The data from this trial are of high strategic importance, as they will directly inform the viability and design of future trials evaluating GSK3915393 as an add-on therapy to the existing standard of care.

Phase 2 Program in Idiopathic Pulmonary Fibrosis (TRANSFORM Study - NCT06317285 / Study ID 220929)

Following the strategic pivot and the foundational Phase 1 program, GSK3915393 advanced into a pivotal Phase 2 efficacy and safety study in its new target indication, IPF.

• Design: The TRANSFORM study is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group trial designed to robustly evaluate the clinical efficacy of GSK3915393.[1] The quadruple masking (participant, care provider, investigator, outcomes assessor) represents a high standard of clinical trial design aimed at minimizing bias.[37]
• Status: The trial is currently active and recruiting participants across multiple countries, including the United States, Canada, and several European nations.[2] The estimated primary completion date is March 2026.[2]
• Population: The study aims to enroll approximately 150 adult participants diagnosed with IPF.[17]
• Endpoints:
• Primary Endpoint: The primary measure of efficacy is the Absolute Change from Baseline in Forced Vital Capacity (FVC) in milliliters (mL) at Week 26.[37] FVC is a standard measure of lung capacity, and its rate of decline is the most widely accepted surrogate endpoint for disease progression in IPF clinical trials.
• Secondary Endpoints: To provide a more detailed picture of the treatment effect over time, the study will also assess the Absolute Change from Baseline in FVC (mL) at earlier time points (Weeks 4, 8, 12, and 18).[37]
• Key Inclusion Criteria: The eligibility criteria are designed to enroll a well-defined IPF population while also reflecting real-world treatment scenarios.
• Confirmed IPF diagnosis within the last 5 years according to established international guidelines (ATS/ERS/JRS/ALAT).[34]
• Chest High-Resolution Computed Tomography (HRCT) findings consistent with a pattern of Usual Interstitial Pneumonia (UIP) or probable UIP.[34]
• Baseline lung function within a specific range: FVC ≥ 45% and Diffusing Capacity for Carbon Monoxide (DLCO) ≥ 25% of predicted normal values.[34]
• Critically, the trial allows for the inclusion of patients who are either on a stable dose of the standard-of-care antifibrotics (nintedanib or pirfenidone) for at least 12 weeks, or those who are not currently receiving these therapies.[34] This design provides data on GSK3915393's effect as both a monotherapy and an add-on therapy.
• Key Exclusion Criteria: The exclusion criteria are designed to ensure patient safety and the integrity of the study data.
• Presence of other clinically significant lung diseases (e.g., COPD, asthma) or other forms of interstitial lung disease (ILD) such as those associated with autoimmune conditions.[34]
• An acute exacerbation of IPF within the 6 months prior to screening.[34]
• Current smokers (including e-cigarettes) or those who have smoked within the past 3 months.[34]
• Significant hepatic dysfunction or clinically significant cardiac abnormalities, including a prolonged QTc interval on ECG.[34]
• Concomitant use of strong or moderate inducers or inhibitors of CYP3A4, or CYP3A4 substrates with a narrow therapeutic index, which cannot be safely discontinued.[34]

The comprehensive and deliberate nature of GSK's clinical development plan for GSK3915393 is noteworthy. The repurposing of the original Phase 1 study to investigate CYP3A4 interactions demonstrates a capital-efficient and pragmatic approach to drug development. Furthermore, the decision to conduct a dedicated Phase 1 study assessing interactions with the standard-of-care, nintedanib, before embarking on large-scale, expensive Phase 3 trials is a clear de-risking strategy. It provides essential safety and dosing information that will be invaluable for designing subsequent studies and for future regulatory discussions. This proactive approach to understanding the drug's profile in the context of combination therapy and global populations suggests that GSK is not merely testing a molecule but is strategically building a comprehensive data package to support multiple potential labeling claims and a broad market launch. This level of meticulous planning is indicative of a high degree of corporate confidence in the asset and a well-formulated, long-term commercial vision for its role in treating IPF.

Trial ID (NCT/IRAS/EudraCT)	Phase	Title/Purpose	Condition(s)	Population	Status	Key Objectives/Endpoints
IRAS 1003407 / 2020-003213-36	1	First-in-Human, Single and Repeat Dose Escalation	Healthy Volunteers & Celiac Disease	Up to 48 healthy adults, 20 celiac patients	Completed	Assess safety, tolerability, PK. Assess PD in celiac patients via gluten challenge (original design).19
NCT04604795	1	Amended DDI study	Healthy Volunteers	Healthy adults	Completed	Evaluate the effect of co-administration with grapefruit juice and itraconazole on the PK of GSK3915393.1
NCT06625489	1	Ethnic PK & Nintedanib DDI	Healthy Volunteers	Healthy adults of Chinese, Japanese, and European ancestry	Completed	Assess safety, tolerability, and PK across different ancestries. Evaluate DDI with nintedanib.2
NCT06317285 / 220929	2	TRANSFORM: Efficacy and Safety of GSK3915393 in IPF	Idiopathic Pulmonary Fibrosis (IPF)	~150 participants with IPF	Recruiting	Primary: Change from baseline in FVC (mL) at Week 26. Secondary: Change from baseline in FVC at earlier timepoints.1

Competitive Landscape and Market Positioning in IPF

The potential success of GSK3915393 is intrinsically linked to its ability to address the significant unmet needs that persist in the Idiopathic Pulmonary Fibrosis (IPF) therapeutic landscape, which is currently defined by two approved agents and a growing pipeline of novel therapies.

Current Standard of Care (SoC)

The treatment paradigm for IPF was transformed by the approval of two antifibrotic drugs: nintedanib (Ofev®), a tyrosine kinase inhibitor, and pirfenidone (Esbriet®).[26] These agents represent the current global standard of care.

• Efficacy: Both nintedanib and pirfenidone have demonstrated a statistically significant ability to slow the rate of disease progression, as measured by the annual decline in Forced Vital Capacity (FVC). Large-scale clinical trials and subsequent real-world meta-analyses have consistently shown this benefit.[25] A 2023 meta-analysis of real-world studies reported a mean change from baseline in percent predicted FVC over 12 months of -1.43% for nintedanib and -0.75% for pirfenidone, confirming their role in preserving lung function compared to the natural history of the disease.[45] However, it is critical to note that these therapies are not curative; they slow progression but do not halt or reverse the underlying fibrotic process.[26]
• Safety and Tolerability: A major limitation of the current SoC is the significant burden of adverse events, which frequently leads to dose reductions, treatment interruptions, or permanent discontinuation.
• Nintedanib is most commonly associated with gastrointestinal side effects, with diarrhea being the most prominent, affecting a majority of patients. Nausea, vomiting, and weight loss are also common.[25]
• Pirfenidone is primarily associated with different adverse events, including photosensitivity reactions, skin rash, and its own profile of gastrointestinal issues such as nausea and dyspepsia.[25]
• Real-world data underscore this challenge, with one large meta-analysis reporting adverse event incidences of 69.7% for nintedanib and 56.4% for pirfenidone. Despite these high rates, treatment discontinuation due to adverse events was around 16% for both drugs, suggesting that patients and physicians manage these side effects to maintain therapy, but highlighting the clear need for better-tolerated options.[45]
• Unmet Need: The limitations of the current SoC define the unmet medical need in IPF. A therapy that could offer superior efficacy in slowing FVC decline, demonstrate a more favorable safety and tolerability profile, or be effectively and safely combined with existing treatments to provide additive benefit would represent a major clinical advance.[26]

Emerging Therapeutic Pipeline

The IPF drug development pipeline is highly active and competitive, with estimates of over 80 companies developing more than 100 pipeline drugs.[28] This robust landscape includes a wide range of mechanisms of action, from monoclonal antibodies and cell therapies to other small molecules targeting different aspects of the fibrotic cascade.[28] Key pipeline assets mentioned in development include BI1015550 (a phosphodiesterase 4B inhibitor), pamrevlumab (a connective tissue growth factor inhibitor), tipelukast (a multi-pathway inhibitor), and PLN-74809 (an integrin inhibitor).[28] The breadth of this pipeline indicates that any new entrant, including GSK3915393, will need to demonstrate a clear and compelling clinical advantage to secure a place in the future treatment algorithm.

Potential Differentiation and Positioning for GSK3915393

GSK3915393 possesses several characteristics that could allow it to be strategically positioned within this competitive market.

• Novel Mechanism of Action: As a direct inhibitor of the TG2 enzyme, GSK3915393 offers a fundamentally different approach to antifibrotic therapy compared to the current SoC and many other pipeline candidates.[1] This novelty is a significant point of differentiation. If the TG2 pathway proves to be a critical, non-redundant node in fibrosis, its inhibition could yield substantial clinical benefits.
• Potential for Improved Safety and Tolerability: Because its mechanism is distinct from that of nintedanib and pirfenidone, there is a strong possibility that its safety profile will not overlap significantly. A therapy that avoids the severe gastrointestinal distress of nintedanib or the dermatological issues of pirfenidone would be highly attractive to both patients and clinicians and could capture a significant patient population intolerant to current options.
• Flexible Market Positioning: GSK's clinical development strategy appears designed to enable a flexible market entry.
• Combination Therapy: The proactive investigation of drug interactions with nintedanib (NCT06625489) and the design of the Phase 2 TRANSFORM trial to include patients already on SoC therapy strongly suggest a primary positioning strategy as an add-on treatment. A successful combination that provides additive efficacy without compounding toxicity could become the new, intensified standard of care for a large segment of the IPF population.
• Monotherapy: Should GSK3915393 demonstrate superior efficacy to the SoC or a markedly improved safety profile, it could also be positioned as a first-line monotherapy. This would be particularly relevant for newly diagnosed patients or those who have previously failed or are intolerant to nintedanib or pirfenidone.

Drug Name (Developer)	Mechanism of Action	Development Phase	Key Efficacy Data (FVC Decline)	Key Safety/Tolerability Issues	Source(s)
Nintedanib (Boehringer Ingelheim)	Tyrosine Kinase Inhibitor (VEGFR, FGFR, PDGFR)	Approved	Slows annual FVC decline; Real-world change in %FVC: -1.43%	Diarrhea, nausea, vomiting, liver enzyme elevation, weight loss	25
Pirfenidone (Roche/Genentech)	Anti-fibrotic, Anti-inflammatory (MoA not fully elucidated)	Approved	Slows annual FVC decline; Real-world change in %FVC: -0.75%	Photosensitivity, rash, nausea, dyspepsia, anorexia	25
GSK3915393 (GSK)	Transglutaminase 2 (TG2) Inhibitor	Phase 2	Efficacy data pending from TRANSFORM study (NCT06317285)	Safety profile under investigation; Phase 1 data not yet public	4
BI 1015550 (Boehringer Ingelheim)	Phosphodiesterase 4B (PDE4B) Inhibitor	Phase 3	Phase 2 showed potential to slow FVC decline	Profile under investigation	28

Strategic Analysis, Regulatory Status, and Future Outlook

The trajectory of GSK3915393 from a celiac disease candidate to a promising Phase 2 asset for Idiopathic Pulmonary Fibrosis (IPF) reflects a series of deliberate strategic choices by GSK. A comprehensive analysis of its potential, inherent risks, and regulatory standing provides a forward-looking perspective on its prospects.

Assessment of Potential and Key Risks

The future value of GSK3915393 is balanced between its significant therapeutic potential and the substantial risks inherent in pharmaceutical development.

• Potential: The primary strength of GSK3915393 lies in its novel mechanism of action (MoA). Targeting TG2 represents a new strategy in the fight against IPF, distinct from the approved standards of care.[1] This novelty carries the potential for either superior efficacy or a non-overlapping, more favorable safety profile. Furthermore, the clinical development program has been astutely designed to explore its utility as both a monotherapy and, perhaps more critically, as a combination therapy with existing agents. This dual-track approach creates a flexible and expansive potential market opportunity, allowing it to be positioned for patients intolerant to current drugs or as an add-on to intensify treatment for the broader IPF population.
• Risks: Despite its promise, the program faces several significant risks.

1. Clinical Trial Risk: The drug is currently in Phase 2, a stage of development notorious for high attrition rates. A recent review of anti-fibrotic drug development highlighted an estimated 83% failure rate for assets transitioning from Phase 2 to Phase 3 across various fibrotic diseases.[30] The outcome of the TRANSFORM study (NCT06317285) is therefore a critical make-or-break milestone. Failure to demonstrate a statistically significant and clinically meaningful benefit in slowing FVC decline would likely terminate the program.
2. Safety Risk: While early-phase studies in healthy volunteers have presumably been completed without major safety signals, the long-term safety profile in an older, co-morbid IPF patient population is unknown. Unforeseen adverse events could emerge during the 26-week TRANSFORM study or in subsequent, longer trials, which could alter its risk-benefit calculus.
3. Competitive Risk: The IPF pipeline is crowded and dynamic.[28] There is a tangible risk that another investigational agent with a different novel mechanism could demonstrate superior efficacy or safety and reach the market before or concurrently with GSK3915393, thereby diminishing its competitive advantage and market share.

Regulatory Status

A notable aspect of the GSK3915393 program is its current regulatory standing, particularly concerning special designations.

• Orphan Drug Designation (ODD): As of the latest available information, GSK3915393 has not been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of IPF.[7]
• Analysis of ODD Status: This absence is conspicuous. IPF is a rare disease that qualifies for ODD, a status that provides significant development incentives, including market exclusivity, tax credits, and fee waivers.[47] Many other drugs in the IPF pipeline have secured this designation.[28] For a sophisticated developer like GSK to have not yet publicly announced the granting of ODD raises several possibilities. The company may be waiting for more robust data from the Phase 2 trial to support its application, or there could be a broader strategic consideration, such as the potential for the drug in other, non-orphan fibrotic indications, which might complicate an ODD application for IPF alone. While an oversight is unlikely, the lack of this designation is a key point that could impact the financial modeling of the drug and is a critical element to monitor in future disclosures.

Future Outlook and Concluding Remarks

GSK3915393 stands as a scientifically well-founded and strategically managed asset in GSK's respiratory pipeline. Its novel mechanism targeting the core fibrotic enzyme TG2 holds genuine promise for advancing the treatment of IPF. The program's development has been characterized by a thoughtful pivot to an area of higher unmet need and a meticulous early-phase trial design that proactively addresses key questions of metabolism and combination use.

The program is now at a crucial inflection point. Its future trajectory will be almost entirely dictated by the results of the ongoing Phase 2 TRANSFORM study.

Key Milestones to Watch:

• Top-line results from the TRANSFORM study (NCT06317285), anticipated after its primary completion in March 2026. This will be the first major test of the drug's efficacy in patients.
• Publication or presentation of full data from the completed Phase 1 studies (NCT04604795 and NCT06625489). These results will provide a detailed understanding of the drug's safety, tolerability, PK, and DDI profile.
• Presentations at major international respiratory conferences, such as the American Thoracic Society (ATS) and European Respiratory Society (ERS) International Congresses, which would provide the first peer-reviewed look at emerging data.[37]
• Any regulatory filings or announcements, particularly regarding the potential application for or granting of Orphan Drug Designation or other expedited pathway designations.

In conclusion, GSK3915393 is a high-potential, high-risk asset. Its success will depend on its ability to deliver a clear clinical benefit in slowing FVC decline while offering a safety and tolerability profile that is either superior to or complementary with the existing standards of care. If the upcoming Phase 2 data are positive, GSK3915393 could be poised to become a cornerstone therapy in the management of IPF, significantly impacting a patient population in desperate need of better therapeutic options.

Works cited

1. GSK3915393 | Advanced Drug Monograph - MedPath, accessed June 19, 2025, https://trial.medpath.com/drug/report/407399d8359cce3b
2. GSK-3915393 Drug Profile - Ozmosi, accessed June 19, 2025, https://pryzm.ozmosi.com/product/20683
3. Pipeline | GSK, accessed June 19, 2025, https://www.gsk.com/en-gb/innovation/pipeline/
4. GSK3915393 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed June 19, 2025, https://synapse.patsnap.com/drug/9a180b8d422f43ef8567480369a93e36
5. synapse-patsnap-com.libproxy1.nus.edu.sg, accessed June 19, 2025, https://synapse-patsnap-com.libproxy1.nus.edu.sg/drug/9a180b8d422f43ef8567480369a93e36#:~:text=The%20drug%20works%20by%20inhibiting,to%20gluten%20in%20celiac%20disease.
6. GSK3915393 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed June 19, 2025, https://synapse-patsnap-com.libproxy1.nus.edu.sg/drug/9a180b8d422f43ef8567480369a93e36
7. GSK 3915393 - AdisInsight - Springer, accessed June 19, 2025, https://adisinsight.springer.com/drugs/800061043
8. GSK3915393: A New Drug for Idiopathic Pulmonary Fibrosis - Clinical trials, accessed June 19, 2025, https://clinicaltrials.eu/inn/gsk3915393/
9. GSK drops celiac disease program acquired in Sitari buyout - Fierce Biotech, accessed June 19, 2025, https://www.fiercebiotech.com/biotech/gsk-drops-celiac-disease-program-acquired-sitari-buyout-and-delivers-blow-bid-avert
10. Transglutaminase 2 and Its Role in Pulmonary Fibrosis - ResearchGate, accessed June 19, 2025, https://www.researchgate.net/publication/51245719_Transglutaminase_2_and_Its_Role_in_Pulmonary_Fibrosis
11. Transglutaminases in fibrosis—overview and recent advances, accessed June 19, 2025, https://journals.physiology.org/doi/full/10.1152/ajpcell.00322.2023
12. Transglutaminase-2: Nature's Glue in Lung Fibrosis? | American Journal of Respiratory Cell and Molecular Biology, accessed June 19, 2025, https://www.atsjournals.org/doi/full/10.1165/rcmb.2021-0209ED
13. Inhibition of Transglutaminase 2, a Novel Target for Pulmonary Fibrosis, by Two Small Electrophilic Molecules, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4068920/
14. Inhibition of Transglutaminase 2, a Novel Target for Pulmonary Fibrosis, by Two Small Electrophilic Molecules | Request PDF - ResearchGate, accessed June 19, 2025, https://www.researchgate.net/publication/258212938_Inhibition_of_Transglutaminase_2_a_Novel_Target_for_Pulmonary_Fibrosis_by_Two_Small_Electrophilic_Molecules
15. Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease - PubMed Central, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9139979/
16. GSK3915393 - Pulmonary Fibrosis Foundation, accessed June 19, 2025, https://www.pulmonaryfibrosis.org/patients-caregivers/medical-and-support-resources/clinical-trials-education-center/pipeline/drug/idiopathic-pulmonary-fibrosis/gsk3915393
17. A study looking at the impact of a new drug, GSK3915393, on the lung function for people with Idiopathic Pulmonary Fibrosis (IPF), accessed June 19, 2025, https://www.actionpf.org/research-study/a-study-looking-at-the-impact-of-a-new-drug-gsk3915393-on-the-lung-function-for-people-with-idiopathic-pulmonary-fibrosis-ipf
18. Transglutaminase 2 and Its Role in Pulmonary Fibrosis - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3208598/
19. GSK3915393 – first doses in humans - NHS Health Research Authority, accessed June 19, 2025, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/gsk3915393-first-doses-in-humans/
20. New therapies in celiac disease - PMC - PubMed Central, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11970589/
21. (PDF) New developments in celiac disease treatments - ResearchGate, accessed June 19, 2025, https://www.researchgate.net/publication/382563448_New_developments_in_celiac_disease_treatments
22. Future Therapies | Celiac Disease Foundation, accessed June 19, 2025, https://celiac.org/about-celiac-disease/future-therapies-for-celiac-disease/
23. Gliadin Sequestration as a Novel Therapy for Celiac Disease: A Prospective Application for Polyphenols - PubMed Central, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7826989/
24. Celiac Disease - Pipeline Insight, 2024 - Research and Markets, accessed June 19, 2025, https://www.researchandmarkets.com/reports/4330940/celiac-disease-pipeline-insight-2024
25. Patient Response to Pirfenidone, Nintedanib for IPF Differs in Real World vs Trials, accessed June 19, 2025, https://www.ajmc.com/view/patient-response-to-pirfenidone-nintedanib-for-ipf-differs-in-real-world-vs-trials
26. A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10945152/
27. Rapid discovery of Transglutaminase 2 inhibitors for celiac disease with boosting ensemble machine learning, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11532751/
28. Idiopathic Pulmonary Fibrosis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA By DelveInsight - Barchart.com, accessed June 19, 2025, https://www.barchart.com/story/news/27172255/idiopathic-pulmonary-fibrosis-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight
29. Strategic report 2024 | GSK, accessed June 19, 2025, https://www.gsk.com/media/11859/strategic-report-2024.pdf
30. A Review of the Current Landscape of Anti-Fibrotic Medicines - ResearchGate, accessed June 19, 2025, https://www.researchgate.net/publication/383942579_A_Review_of_the_Current_Landscape_of_Anti-Fibrotic_Medicines
31. TITLE PAGE - ClinicalTrials.gov, accessed June 19, 2025, https://cdn.clinicaltrials.gov/large-docs/95/NCT04604795/Prot_000.pdf
32. Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy ... - TrialScreen, accessed June 19, 2025, https://app.trialscreen.org/trials/phase-1-celiac-disease-to-evaluate-safety-tolerability-pharmacokinetics-trial-nct04604795
33. A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib | TrialScreen, accessed June 19, 2025, https://app.trialscreen.org/trials/phase-1-to-evaluate-safety-tolerability-blood-levels-gsk3915393-administered-trial-nct06625489
34. A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) - ClinicalTrials.Veeva, accessed June 19, 2025, https://ctv.veeva.com/study/a-study-to-evaluate-the-efficacy-and-safety-of-gsk3915393-in-participants-with-idiopathic-pulmonary
35. A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study (TRANSFORM) to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) - PL - Orphanet, accessed June 19, 2025, https://www.orpha.net/en/research-trials/clinical-trial/696473?name=&mode=name&country=&recruiting=0&terminated=0
36. A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Temple Health, accessed June 19, 2025, https://www.templehealth.org/services/lung/research-clinical-trials/-study-to-evaluate-efficacy-and-safety-of-gsk915393-in-participants-with-idiopathic-pulmonary-fibrosis
37. Welcome to GSK Clinical Trials, accessed June 19, 2025, https://www.gsk-studyregister.com/en/trial-details/?id=220929
38. Clinical Trial Results - GSK Study Register, accessed June 19, 2025, https://www.gsk-studyregister.com/en/results/?Keyword=&Status=RECSTATUS_RECRUITING~RECSTATUS_NOT_YET_RECRUITING&Latitude=51.165691&Longitude=10.451526&MileRadius=100&LocationName=Deutschland&Conditions=&phases=&HasCTGovResult=&patientLevel=&gender=&ageRange=&studyType=&documents=&SponsorUnits=
39. Study on the Effects of GSK3915393 for Patients with Idiopathic Pulmonary Fibrosis, accessed June 19, 2025, https://clinicaltrials.eu/trial/study-on-the-effects-of-gsk3915393-for-patients-with-idiopathic-pulmonary-fibrosis/
40. A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Clinical Research Trial Listing - CenterWatch, accessed June 19, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06317285/a-study-to-evaluate-the-efficacy-and-safety-of-gsk3915393-in-participants-with-idiopathic-pulmonary-fibrosis-ipf?country=Canada&city=Ajax%25252C%252520Ontario
41. A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) - ClinConnect, accessed June 19, 2025, https://clinconnect.io/trials/NCT06317285
42. Comparison of the Effects of Nintedanib and Pirfenidone on Pulmonary Function Test Parameters and Radiological Findings in Patients with Idiopathic Pulmonary Fibrosis: A Real-Life Study - MDPI, accessed June 19, 2025, https://www.mdpi.com/1648-9144/61/2/283
43. Full article: Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre, accessed June 19, 2025, https://www.tandfonline.com/doi/full/10.1016/j.pulmoe.2018.06.003
44. Use of Nintedanib and Pirfenidone in Non–Idiopathic Pulmonary Fibrosis Lung Disease | American Journal of Respiratory and Critical Care Medicine, accessed June 19, 2025, https://www.atsjournals.org/doi/full/10.1164/rccm.202012-4356RR
45. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis - PubMed, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/38963453/
46. Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire, accessed June 19, 2025, https://www.globenewswire.com/news-release/2025/01/28/3016700/0/en/Pulmonary-Fibrosis-Clinical-Trial-Pipeline-Appears-Robust-With-110-Key-Pharma-Companies-Actively-Working-in-the-Therapeutics-Segment-DelveInsight.html
47. Designating an Orphan Product: Drugs and Biological Products - FDA, accessed June 19, 2025, https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products
48. Medical products for rare diseases and conditions - FDA, accessed June 19, 2025, https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions
49. FDA Grants Orphan Drug Designation to Elraglusib for Soft Tissue Sarcomas - OncLive, accessed June 19, 2025, https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-elraglusib-for-soft-tissue-sarcomas
50. 21 CFR Part 316 -- Orphan Drugs - eCFR, accessed June 19, 2025, https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-316
51. Drugs and biologics receiving FDA orphan drug designation: an analysis of the most frequently designated products and their repositioning strategies - PubMed, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/35548705/
52. Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer, accessed June 19, 2025, https://actuatetherapeutics.com/press_releases/actuate-therapeutics-receives-ema-orphan-medicinal-product-designation-for-elraglusib-for-the-treatment-of-pancreatic-cancer/
53. Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome, accessed June 19, 2025, https://investors.quoinpharma.com/news-releases/news-release-details/quoin-pharmaceuticals-announces-european-medicines-agency-ema/
54. Orphan designation: Overview | European Medicines Agency (EMA), accessed June 19, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/orphan-designation-overview
55. Training recording: how to submit an application for orphan medicinal product designation using IRIS - YouTube, accessed June 19, 2025, https://www.youtube.com/watch?v=74VzidWJwsA
56. Public - List of Opinions on Orphan Medicinal Product Designation - IRIS, accessed June 19, 2025, https://iris.ema.europa.eu/odpublicregister/
57. Orphan Drug Designation in the US, EU & GB - Scendea, accessed June 19, 2025, https://www.scendea.com/orphan-drug-designation-in-the-us-eu-gb
58. Orphan Designations/Approvals - Drug Database, accessed June 19, 2025, https://drugdatabase.info/orphan-designations-approvals/
59. Orphan Drugs - HRSA, accessed June 19, 2025, https://www.hrsa.gov/opa/program-requirements/orphan-drug-exclusion
60. Search Orphan Drug Designations and Approvals - accessdata.fda.gov, accessed June 19, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/
61. Search Orphan Products Grant Program - accessdata.fda.gov, accessed June 19, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopdgrants/
62. Search for an orphan drug - Orphanet, accessed June 19, 2025, https://www.orpha.net/en/drug
63. List of the marketing authorisations - EURORDIS-Rare Diseases Europe, accessed June 19, 2025, https://www.eurordis.org/information-support/list-of-the-marketing-authorisations/
64. FORM 10-K United Therapeutics Corporation, accessed June 19, 2025, https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/press-releases/2024/uthr-4q24-10k.pdf
65. Strategic report 2024 | GSK, accessed June 19, 2025, https://www.gsk.com/media/vounsu2k/strategic-report-2024.pdf
66. Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society's (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension, accessed June 19, 2025, https://www.merck.com/news/merck-to-present-new-clinical-and-outcomes-research-data-at-the-american-thoracic-societys-ats-2025-international-conference-demonstrating-commitment-to-advancing-research-in-pulmonary-arte/
67. Breaking Clinical Trials Session Unveils New Insights in Pulmonary Medicine, accessed June 19, 2025, https://www.atsconferencenews.org/breaking-clinical-trials-session-unveils-new-insights-in-pulmonary-medicine/
68. GSK continues to advance the future of respiratory medicine and patient care with new data at ATS, accessed June 19, 2025, https://www.gsk.com/en-gb/media/press-releases/gsk-continues-to-advance-the-future-of-respiratory-medicine/
69. Respiratory - Scientific Meetings - GSK US Medical Affairs, accessed June 19, 2025, https://gskusmedicalaffairs.com/respiratory/scientific-meetings/ats-2025/
70. ATS 2026 International Conference, accessed June 19, 2025, https://conference.thoracic.org/
71. final-ers-24-curtain-raiser.pdf - GSK, accessed June 19, 2025, https://www.gsk.com/media/11531/final-ers-24-curtain-raiser.pdf
72. ERS Congress - Home - European Respiratory Society, accessed June 19, 2025, https://www.ersnet.org/congress-and-events/congress/
73. ERS - GSKPro for Healthcare Professionals, accessed June 19, 2025, https://gskpro.com/en-sa/campaign/ers/
74. ERS - Congress and events - Official Website - European Respiratory Society, accessed June 19, 2025, https://www.ersnet.org/congress-and-events/
75. European Respiratory Society (ERS) - 34th Annual Congress - AstraZeneca Medical Information, accessed June 19, 2025, https://medicalinformation.astrazeneca-us.com/home/congress-library/ers-2024-congress-library-details.html